Miguel Ángel Arrabal-Polo

Dr. Miguel Ángel Arrabal-Polo

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2014 in Canadian Urological Association Journal
Verified
Journal Article
Open access
PDF file
JTJavier Tinaut-Ranera
Javier Tinaut-Ranera
Miguel Ángel Arrabal-PoloMiguel Ángel Arrabal-Polo
Miguel Ángel Arrabal-Polo
SMSergio Merino-Salas
Sergio Merino-Salas
MNMercedes Nogueras-Ocaña
Mercedes Nogueras-Ocaña
VLVictor Lopez-Leon
Victor Lopez-Leon
AZArmando Zuluaga-Gomez
Armando Zuluaga-Gomez
We analyze the outcomes of patients with urethral stricture who underwent surgical treatment within the past 5 years. This is a retrospective study of male patients who underwent surgery for urethral stricture at our service from January 2008 to June 2012. We analyzed the comorbidities, type, length and location of the stricture and the surgical treatment outcome after endoscopic urethrotomy, urethroplasty or both. In total, 45 patients with a mean age of 53.7 ± 16.7 years underwent surgical treatment for urethral stricture. Six months after surgery, 46.7% of the patients had a maximum urinary flow greater than 15 mL/s, whereas 87.3% of the patients exhibited no stricture by urethrography after the treatment. The success rate in the patients undergoing urethrotomy was 47.8% versus 86.4% in those undergoing urethroplasty (p = 0.01). Twenty percent of the patients in whom the initial urethrotomy had failed subsequently underwent urethroplasty, thereby increasing the treatment success. In most cases, the treatment of choice for urethral stricture should be urethroplasty. Previous treatment with urethrotomy does not appear to produce adverse effects that affect the outcome of a urethroplasty if urethrotomy failed, so urethrotomy may be indicated in patients with short strictures or in patients at high surgical risk.

23 March 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Miguel Ángel Arrabal-PoloMiguel Ángel Arrabal-Polo
Miguel Ángel Arrabal-Polo
MSM Teresa Melgarejo Segura
M Teresa Melgarejo Segura
YYYaiza Maria Yáñez-Castillo
Yaiza Maria Yáñez-Castillo
AMAna Morales Martínez
Ana Morales Martínez
MVManuel Pareja Vílchez
Manuel Pareja Vílchez
MMMiguel Arrabal Martín
Miguel Arrabal Martín

19 May 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YYY. M. Yáñez-Castillo
Y. M. Yáñez-Castillo
MMM. T. Melgarejo-Segura
M. T. Melgarejo-Segura
CFC. Funes-Padilla
C. Funes-Padilla
MFM. E. Folgueral-Corral
M. E. Folgueral-Corral
JGJ. V. García-Larios
J. V. García-Larios
MAM. Arrabal-Martín
M. Arrabal-Martín

1 January 2022 in Archivos Espanoles de Urologia
Verified
Journal Article
Closed access
YYYaiza Maria Yáñez-Castillo
Yaiza Maria Yáñez-Castillo
Miguel Ángel Arrabal-PoloMiguel Ángel Arrabal-Polo
Miguel Ángel Arrabal-Polo
Introduction: Platelet rich plasma is a product obtained from vein who...

1 September 2007 in Archivos Espanoles de Urologia
Verified
Journal Article
Open access
PDF file
MMMiguel Arrabal Martín
Miguel Arrabal Martín
FGFrancisco Valle Díaz de la Guardia
Francisco Valle Díaz de la Guardia
APAntonio Jiménez Pacheco
Antonio Jiménez Pacheco
VLVíctor López León
Víctor López León
Miguel Ángel Arrabal-PoloMiguel Ángel Arrabal-Polo
Miguel Ángel Arrabal-Polo
AGArmando Zuluaga Gómez
Armando Zuluaga Gómez
Current treatment of hypercalciuria is still controversial, not being recommended calcium restriction since it may cause a negative balance with important consequences to bone metabolism. In adults, the use of biphosphonates (sodium alendronate) has shown a good response. Biphosphonates are synthetic analogs of the endogenous pirophosphate. Pirophosphate is the simplest form of phosphate. In 1968, Fleisch demonstrated that inorganic pirophosphate inhibits the precipitation of calcium phosphate. The differences between various biphosphonates are in the safety margin between their inhibitor effect for bone resorption and the inhibitor effect for mineralization; bone resorption inhibition has been their most widely spread application. The objective of this work is to analyze the clinical and biochemical effect of biphosphonates in patients with hypercalciuria, osteopenia and renal lithiasis. From 1996 to 2006 we treated 25 cases of recurrent renal lithiasis associated with hypercalciuria and primary or secondary bone mass loss. All cases were treated with sodium alendronate and oral calcium (1000-1200 mg/day). We analyze tolerance and treatment compliance, side effects, biochemical effects on blood and urine, effect on bone mineralization, and the outcome of lithiasic disease before and after treatment. All patients have followed the recommendations for the administration of the drug (sodium alendronate 10 mg/day or 70 mg/week), have had good tolerance without relevant side effects, and no one quit treatment. 76% of the cases have had remission of the lithogenesis activity and 24% reduction, and all cases have had an increase of bone mineralization. In this group of selected patients with recurrent lithiasis and osteopenia the treatment with biphosphonates alone or associated with thiazide diuretics has given good results in renal lithiasis control and bone demineralization. The extension of indications should be analyzed in a multicentric randomized study.

1 January 2021
Verified
Journal Article
Closed access
AMAna Morales-Martinez
Ana Morales-Martinez
MMMa Teresa Melgarejo-Segura
Ma Teresa Melgarejo-Segura
Miguel Ángel Arrabal-PoloMiguel Ángel Arrabal-Polo
Miguel Ángel Arrabal-Polo